New options for early diagnosis and prevention of HPV-associated cervical lesions
https://doi.org/10.21518/2079-701X-2015-XX-72-77
Abstract
The review examines the relationship of human papillomavirus and its role in cervical intraepithelial neoplasia (CIN) and cervical cancer. The most informative methods of diagnostics (immunohistochemical, molecular-genetic and other) and treatment of HPV-related cervical lesions are described.
Keywords
human papillomavirus,
cervical intraepithelial neoplasia,
liquid-based cytology,
E6,
E7 oncoproteins,
r16INK4a/Ki67 double staining,
HPV testing,
microRNA,
вирус папилломы человека,
цервикальная интраэпителиальная неоплазия,
жидкостная цитология,
онкопротеины Е6 и Е7,
р16INK4а/Ki67 двойное окрашивание,
ВПЧ-тестирование,
микро-РНК
About the Authors
V. N. Prilepskaya
Scientific center for obstetrics, gynecology and perinatology named after V.I. Kulakov, Russia’s Ministry of Health
Russian Federation
Russian Federation
G. R. Bayramova
Scientific center for obstetrics, gynecology and perinatology named after V.I. Kulakov, Russia’s Ministry of Health
Russian Federation
Russian Federation
E. A. Kogan
Scientific center for obstetrics, gynecology and perinatology named after V.I. Kulakov, Russia’s Ministry of Health
Russian Federation
Russian Federation
V. F. Chernova
Scientific center for obstetrics, gynecology and perinatology named after V.I. Kulakov, Russia’s Ministry of Health
Russian Federation
Russian Federation
A. N. Okushko
Scientific center for obstetrics, gynecology and perinatology named after V.I. Kulakov, Russia’s Ministry of Health
Russian Federation
Russian Federation
References
1. World Health Organization International Agency for research of Cancer GLOBOCAN 2012; Estimated cancer incidence, mortality and prevalence worldwide in 2012.Geneva:2012
2. Russian FederationHuman Papillomavirus and Related Cancers, Fact Sheet 2013 HPV Information Centre 2014.
3. Benard VB, Watson M, Castle PE, Saraiya M. Cervical Cancer Rates Among Young Females in the United States. ObstetGynecol 2012;120:1117-23.
4. Киселев Ф.Л. Генетические и эпигенетические факторы прогрессии опухолей шейки матки / Ф.Л. Киселев // Вестн. Росс. АМН.- 2007.- №11.-С.25-32.
5. Wheeler C. M., Hunt W. C., Schiffman M., Castle P. E. Human papillomavirus genotypes and the cumulative 2-years risk of cervical precancer // J. Infect. Dis. 2006: 194: 1291-1299
6. Орехова Е.К., Хачатурян А.Р., Современные возможности папилломавирусной инфекции: обзор мировых исследований //Журналъ акушерства и женскихъ болезней. - 2014. - Выпуск 3, том LXII, - С. 82-88
7. Роговская С. И. Папилломавирусная инфекция у женщин и патология шейки матки: в помощь практикующему врачу. Изд. 2-е. М.: ГЭОТАР-Медиа, 2008. 192 с.
8. Giannella L, Fodero C, Boselli F, Mfuta K, Rubino T, Prandi S. Age-related changes in the diagnostic assessment of women with severe cervical lesions. Climacteric. 2015 Jan 20:1-18
9. BasemanJ.G. andKoutskyL.A. 2005. The epidemiology of human papillomavirus infections. Journal of Clinical Virology, 32(1): 16-24.
10. zurHausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis.//J.Natl. Cancer Inst.-2000.-v.92(9).-p.690-698.
11. Philip J. Disaia, William T. Creasman. Клиническая онкогинекология. Пер. с англ. под ред. Е. Г. Новиковой. М.: ООО «Рид Элсивер», 2011. Т. 1. 316 с.: ил.
12. Wheeler C. M., Hunt W. C., Schiffman M., Castle P. E. Human papillomavirus genotypes and the cumulative 2-years risk of cervical precancer // J. Infect. Dis. 2006: 194: 1291-1299.
13. Wheeler C. M. et al. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer // J Infect Dis. 2006: 194: 1291-1299.
14. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer. 2010; 127(12): 2893- 917.
15. Zaravinos A., Mammas I.N., Sourvinos G., Spandidos D.A. Molecular detection methods of human papillomavirus ( HPV). Int. J. Biol. Markers. 2009; 24(4): 215-22
16. American Society for Colposcopy and Cervical Pathology Journal of Lower Genital Tract Disease, Volume 16, Number 3, 2012, 00Y00
17. http://www.asccp.org/About-ASCCP/News-Announcements
18. Phillips S1, Garland SM2, Tan JH3, Quinn MA3, Tabrizi SN4. Comparison of the Roche Cobas(®) 4800 HPV assay to Digene Hybrid Capture 2, Roche Linear Array and Roche Amplicor for Detection of High-Risk Human Papillomavirus Genotypes in Women undergoing treatment for cervical dysplasia. J ClinVirol. 2015 Jan;62:63-5. doi: 10.1016/j.jcv.2014.11.017. Epub 2014 Nov 18.
19. World Health Organization (WHO). Comprehensivecervical cancer control. A guide to essential practice(http://www.who.int/reproductivehealth/publications/cancers/cervical-cancerguide/en/) December 2014.
20. OgunmodedeF1, Yale SH, Krawisz B, Tyler GC, Evans AC. Human papillomavirus infections in primary care. Clin Med Res. 2007 Dec;5(4):210-7. Epub 2007 Dec 17.
21. Arbyn M., Verdoodt F., Snijders P.J., Verhoef V.M., Suonio E., Dillner L. et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014; 15(2): 172-83
22. Denton K.J., Bergeron C., Klement P., Trunk M.J., Keller T., Ridder R.; European CINtec Cytology Study Group. The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results. Am. J. Clin. Pathol. 2010; 134(1): 12-21
23. РоговскаяС.И. Папилломавируснаяинфекцияуженщинипатологияшейки .М.: ГЭОТАР -Медиа;2008
24. Shin K-H., Ahn J.H., Kang M.K. et al. HPV-16 E6 oncoprotein impairs the fidelity of DNA endjoining via p53-dependent and -independent pathways. Intern J Oncol. 2006; 28: 209- 215
25. Klaes R., Friedrich T., Spitkovsky D., Ridder R., Rudy W., Petry U. et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int. J. Cancer. 2001; 92(2): 276-84.
26. Castle PE1, Dockter J, Giachetti C, Garcia FA, McCormick MK, Mitchell AL, Holladay EB, Kolk DP. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res. 2007 May 1;13(9):2599-605.
27. Sotlar K1, Stubner A, Diemer D, Menton S, Menton M, Dietz K, Wallwiener D, Kandolf R, Bültmann B. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J MedVirol. 2004 Sep;74(1):107-16. Karlsen F ,Keegan H, McInerney J, Pilkington L, Grønn P, Silva I, Bolger N, Logan C, Furuberg L, O'Leary J, Martin C. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens. J Virol Methods. 2009 Jan;155(1):61-6.
28. Белоцерковцева 1 , Л. В. Коваленко 1 , С. В. Лескова1 .Роль экспрессии онкобелка Е7 в ранней диагностике шейки матки. УДК 618.146-006:577.122.5
29. Bergeron C., Ordi J., Schmidt D., Trunk M.J., Keller T., Ridder R.; European CINtec Histology Study Group. Conjunctive p16 (INK4a) testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am. J. Clin. Pathol. 2010; 133(3): 395- 406.
30. Wentzensen N., Schwartz L., Zuna R.E., Smith K., Mathews C., Gold M.A. et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin. Cancer Res. 2012; 18(15): 4154-62. Ikenberg H1, Bergeron C, Schmidt D, Griesser H Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst. 2013 Oct 16;105(20):1550-7. doi: 10.1093/jnci/djt235. Epub 2013 Oct 4.
31. Протасова А.Э.Клиническая оценка и фармакоэкономический анализ диагностики и лечения основных злокачественных опухолей женских гениталий в амбулаторных условиях.Автор.дис..доктора мед.наук СПб:2011
32. WangX., Wang H.K., Li Y., Hafner M., Banerjee N.S., Tang S., Briskin D., Meyers C., Chow L.T., Xie X., Tuschl T., Zheng Z.M.
33. MicroRNAsarebiomarkersofoncogenichumanpapillomavirusinfections. ProcNatlAcadSciUSA.2014 Mar 18; 111(11):4262-7. doi: 10.1073/pnas.1401430111. Epub 2014 Mar 3.
34. House M., Guo M., Iacobuzio-Donahue C., Herman J. Molecular progression of promoter of promoter methylation in intraductalpapillarymucinous neoplasms of the pancreas. //Carcinogenesis. 2003. - Feb 24(2): 193-198.
35. Киселева Н.П., Киселев Ф.Л. Эпигенетические изменения и. канцерогенез. //Канцерогенез. М1,2000. - С. 93-105.
36. ЗалетаевД.В.,Немцова М., Стрельников В, и др. Аномальноеметилирование генов- супрессоров опухолевого роста какпотенциальный маркер предраковых состояний шейки матки. //Клиническая лабораторная диагностика. 2004. - №3.-С.46-49.
37. WidschwendterA.,MullerH., FieglH. etal. DNAmethylationinserumandtumors of cervical cancer patients. // Clinical cancer research. 2004. - Vol. 10.-P. 565-571
38. Wang ZM1. PAX1 methylation analysis by MS-HRM is useful in triage of high-grade squamous intraepithelial lesions. Asian Pac J Cancer Prev. 2014;15(2):891-4.
39. Стерн П. Л., Китченер Г. С. пер с анг. под общ.редакд. РАМН Г. Т. Сухих, проф. В.Н. Прилепской. Вакцина для профилактики РШМ. М.: МЕДпресс-информ, 2009. 192 с.:ил.
40. Прилепская В. Н., Роговская С. И., Кондриков Н. И., Сухих Г. Т.Папилломавирусная инфекция: диагностика, лечение и профилактика. М.: МЕДпресс-информ, 2007. Шабалова И.П. Цитологический атлас. Критерии диагностики заболеваний шейки матки. М.:Триада-X; 2001. del Pino M., Garcia S., Fusté V., Alonso I., Fusté P., Torné A., Ordi J. Value of p16 (INK4a) as a marker of progression/regression in cervical intraepithelial neoplasia grade 1. Am. J. Obstet. Gynecol. 2009; 201(5): 488. el-7. Е. Б. Рудакова Папилломавирусная инфекция и влагалищный микробиоценоз Лечащий врач, 2012, № 3,с. 1-4.
41. УсовецкийИ.А.Применение нового отечественного иммуномодулятораГалавит в лечении урогенитальных инфекций. «TERRA MEDICA NOVA» 2005, №1, с. 2-4.
42. Исаков В.А., Архипова Е.И., Ермоленко Д.К. Применение иммуномодулятора Галавит в терапии папилломавирусной инфекции. «TERRA MEDICA NOVA» №1 2005.
Review
For citations:
Prilepskaya VN, Bayramova GR, Kogan EA, Chernova VF, Okushko AN. New options for early diagnosis and prevention of HPV-associated cervical lesions. Meditsinskiy sovet = Medical Council. 2015;(XX):72-77. (In Russ.) https://doi.org/10.21518/2079-701X-2015-XX-72-77
Views:
616
Email this article 